The San Antonio Breast Cancer Symposium (#SABCS) starts next week (Dec 4 – 8).
Last year at SABCS, Dr Jose Baselga presented the results of the CLEOPATRA phase III trial in HER2+ metastatic breast cancer.
An impressive 6.1 months increase in progression free survival (PFS) of 18.5 vs. 12.4 months was seen by the addition of pertuzumab (Perjeta) to the combination of trastuzumab (Herceptin) and chemotherapy (docetaxel). You can read more on Pharma Strategy Blog.
Earlier this year, following pertuzumab’s approval by the FDA, Roche/Genentech announced that the CLEOPATRA study results demonstrated that women taking the pertuzumab, trastuzumab and chemotherapy combination lived significantly longer, i.e. an overall survival (OS) benefit. The exact amount of the OS benefit is not yet known, but the data will be presented next week in San Antonio. This is exciting news!
I will not be at SABCS due to the overlap with ASH, but like many will be following via Twitter. Without wishing to offend anyone not included, here’s my starting list of people I will be following for news and commentary:
- AACR PR Manager TaraGYates @TaraGYates
- AACR’s magazine Cancer Today for survivors and caregivers @CancerTodayMag
- Cure Magazine @cure_magazine
- Roche at Congresses @congressconnect (update Dec 6: surprising – tweeted that not covering SABCS this year)
- Boehringer @Boehringer (added Dec 3)
Patient Advocates/Advocacy & Support Groups
- AnneMarie Ciccarella @chemobrainfog
- CJ Corneliussen-James @CJMeta
- Lori Marx-Rubiner @regrounding
- Jody Schoger @jodyms
- Inspire @teaminspire
- TNBC Foundation @TNBCFoundation
I am sure there will be a lot of people contributing to the conversation from San Antonio so do follow the #SABCS Twitter hashtag for additional people you may wish to follow.
In case you missed it, here is the Pharma Strategy Blog video from SABCS 2011, presented by Sally Church, PhD (@MaverickNY):